Results 231 to 240 of about 684,663 (243)
Some of the next articles are maybe not open access.
PD-L1 expression in meningiomas
Journal of Clinical Neuroscience, 2018The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies.
openaire +2 more sources
PD-L1 expression in sebaceous carcinomas
Cancer Immunology, Immunotherapy, 2021Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. Tumoral immune microenvironment characterization is essential for considering immune checkpoint inhibitors as a treatment option.A total of 173 resected SCs were reviewed. Clinical information, lesion size, and location were collected.
Maelle Saliba +8 more
openaire +2 more sources
Upregulation of PD-L1 in Senescence and Aging
Molecular and Cellular Biology, 2022Cellular senescence is a stable form of cell cycle arrest associated with proinflammatory responses. Senescent cells can be cleared by the immune system as a part of normal tissue homeostasis. However, senescent cells can also accumulate in aged and diseased tissues, contributing to inflammation and disease progression.
Angelique Onorati +6 more
openaire +2 more sources
Cancer Immunology, Immunotherapy, 2016
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Ahmad, Shamaila Munir +3 more
openaire +3 more sources
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Ahmad, Shamaila Munir +3 more
openaire +3 more sources
Science Signaling, 2017
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +1 more source
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +1 more source
RSC Medicinal Chemistry
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
Arkhiv patologii, 2019
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
G A, Frank +8 more
openaire +2 more sources
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
G A, Frank +8 more
openaire +2 more sources
Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +3 more sources
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +3 more sources
[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Bulletin du cancer, 2018The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers.
Audrey, Monneur +2 more
openaire +1 more source
Expression of PD-L1 in mastocytosis
Journal of the American Academy of Dermatology, 2016Lawrence F. Kuklinski, Jinah Kim
openaire +2 more sources